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Intermittent fever in a patient with apparent fatty liver
Clinical presentation
A 41 year old female presented with non-specific abdominal
pain and intermittent hyperpyrexia (38 C˚); she had been
recently treated for apical granulomas with an otherwise
negative medical history and clinical examination, including
a normal body mass index. At presentation the patient had
not received any medication for the past two weeks.
Laboratory investigations were within normal limits apart
from: erythrocyte sedimentation rate 30 mm (normal range
5–20), aspartate aminotransferase/alanine aminotransferase
49/62 U/l (normal range 13–37/7–43), and serum alkaline
phosphatase 168 U/l (normal range 44–132). Blood cultures
were negative.
A chest x ray revealed no lesion and liver sonography
demonstrated a patchy hypo-hyper-echoic polycyclic area in
the anterior-superior parenchyma compatible with segmental
fatty liver. Thoracic abdominal contrastographic computed
tomography confirmed a large regular polycyclic borders area,
hypodense compared with the remaining parenchyma, with
no mass effect and/or any displacement of the vessels,
resembling focal fatty areas (fig 1A, B); no other pathological
signs were found except for small lymphoadenopathies
adjacent to frenic pillars.
Question
Is it really fatty liver? What is your diagnosis?
See page 823 for answer
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Figure 1 Direct (A) and iodinated (B) spiral computed tomography scans revealed regular polycyclic borders area (white arrows), hypodense
compared with remaining parenchyma, with no mass effect and/or any displacement of the parenchymal vessels.
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Answer
From question on page 774
Magnetic resonance examination confirmed liver alteration
(fig 2A, B) but without features typical of a fatty area
(usually showing high signal intensity at T1 and high-
medium at T2 acquisitions). Full biopsy demonstrated diffuse
homogeneous stromal lymphocytic infiltration of the par-
enchyma (fig 3).
In the case of primary hepatic lymphoma, the most
probable finding is a single well defined homogeneous lesion,
hypoechoic at ultrasound and low attenuation at computed
tomography: however, no group of signs is specific for its
diagnosis and biopsy is always required. Conversely, second-
ary liver lymphoma can have a greater variety of appearances
and is more likely to be multiple/diffusely infiltrating lesions.
Nevertheless, the exclusive diffuse infiltration of the upper
portions of the organ with regular borders and without vessel
displacement constitutes a very unusual presentation. This is
probable due to stromal infiltration by slow growth, soft
tissue of small lymphomatous cells without great nodules;
consequent ultrasound waves scattering could also explain
the patchy hypo-hyper-echoic pattern. doi: 10.1136/gut.2005.078378
Figure 2 Magnetic resonance scans confirming the presence of ultrasound/computed tomography detected area (white arrows), which appears
hypointense at T1 (A) and hyperintense at T2 (B) weighted acquisition.
Figure 3 Haematoxylin-eosin staining shows diffuse lymphomatous
invasion of liver tissue (magnification610).
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